In one paragraphArticle in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors at 3 institutions in 2 countries.
Jessica C HargartenLaboratory of Clinical Immunology and Microbiology (LCIM), Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID 0000-0001-8724-9463 Kenneth SsebambuliddeLaboratory of Clinical Immunology and Microbiology (LCIM), Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID 0000-0002-8125-0698 Seher H AnjumLaboratory of Clinical Immunology and Microbiology (LCIM), Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Malcolm J VaughanLaboratory of Clinical Immunology and Microbiology (LCIM), Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID 0009-0006-0645-6510 Jintao XuDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.ORCID 0000-0002-9946-8601 Brian SongResearch Service, Ann Arbor VA Healthcare System, Department of Veterans Affairs Health System, Ann Arbor, MI, USA.
Anutosh GangulyResearch Service, Ann Arbor VA Healthcare System, Department of Veterans Affairs Health System, Ann Arbor, MI, USA.ORCID 0000-0002-7228-7827 Yoon-Dong ParkLaboratory of Clinical Immunology and Microbiology (LCIM), Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Terri ScottLaboratory of Clinical Immunology and Microbiology (LCIM), Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Dima A HammoudCenter for Infectious Disease Imaging (CIDI), Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0001-7406-7871 Michal A OlszewskiDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.ORCID 0000-0001-7474-0843 Peter R WilliamsonLaboratory of Clinical Immunology and Microbiology (LCIM), Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID 0000-0002-7953-2178 National Institutes of Health · USVA Ann Arbor Healthcare System · USNational Institutes of Health Clinical Center · US
Funding
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDII01BX000596 · VA · VA SALT LAKE CITY HEALTHCARE SYSTEM · PI KISHORE, BELLAMKONDA K · 2011 to 2019
–Modulation of Pulmonary Defenses in Pathobiology of Chronic InfectionsI01BX000656 · VA · VETERANS HEALTH ADMINISTRATION · PI OLSZEWSKI, MICHAL A · 2011 to 2025
–Offsetting CNS inflammatory damage with anti-CXCR3 antibody immunotherapyI21BX006349 · VA · VETERANS HEALTH ADMINISTRATION · PI OLSZEWSKI, MICHAL A · 2024 to 2025
–BLRD Research Career Scientist Award ApplicationIK6BX005966 · VA · VETERANS HEALTH ADMINISTRATION · PI OLSZEWSKI, MICHAL A · 2022 to 2025
–BLRD VA I01 BX000596BLRD VA I01 BX000656BLRD VA I21 BX006349BLRD VA IK6 BX005966
6 · The paper itselfAbstract
Post-infection inflammatory syndromes have been increasingly recognized as a cause of host damage in a variety of infectious diseases including tuberculosis, bacterial meningitis, and COVID-19. Recently, a post-infectious inflammatory response syndrome (PIIRS) was described in non-HIV-infected cryptococcal fungal meningoencephalitis (CM) as a major cause of mortality. Inflammatory syndromes are particularly severe in neurological infections due to the skull's rigid structure which limits unchecked tissue expansion from inflammatory-induced edema. In the present studies, neurologic transcriptional pathway analysis utilizing a murine PIIRS model demonstrated a predominance of Janus kinase/signal transducer and activator of transcription (JAK/STAT) activation. JAK/STAT inhibitor treatment resulted in improvements in CNS damage markers, reductions in intrathecal CD44
Identifiers
PMID38293201
PMCPMC10827263
OpenAlexW4391077430
What OpenQuestion holds
Textmetadata
LicenceCC0
Read underepoch 390